Eltrombopag (ELT) is a thrombopoietin receptor agonist (TPO-RA), currently indicated for the treatment of immune thrombocytopenia (ITP), hepatitis C-associated thrombocytopenia and severe aplastic anemia (SAA) (Gilreath et al., 2021). This evidence concerns the gene TPO and autoimmune thrombocytopenic purpura.